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Summary In a series of 882 retinoblastoma patients, 384 known to have the genetic form of the disease and
498 others, 30 patients developed second primary neoplasms. The spectrum of these second neoplasms is
discussed in relation to the forms of treatment used for the retinoblastoma. Cumulative incidence rates of
second tumours in the whole series are 2.0% at 12 years after diagnosis and 4.2% after 18 years. For patients
with the genetic form of retinoblastoma the cumulative incidence rate after 18 years is 8.4% for all second
neoplasms and 6.0% for osteosarcomas alone. The inherent risk among survivors from genetic retinoblastoma
of developing an osteosarcoma, excluding all possible effects of treatment, is estimated to be 2.2% after 18
years. Within the field of radiation treatment the cumulative incidence rate for all second neoplasms after 18
years is 6.6% and for osteosarcomas alone 3.7%. There is some evidence that patients with genetic
retinoblastoma are particularly sensitive to the carcinogenic effects of radiation. The results also suggest that
the use of cyclophosphamide may increase the risk of second primary neoplasms in patients with genetic
retinoblastoma. The incidence rates of second primary neoplasms in retinoblastoma survivors reported here
are lower than those quoted for previously published series. Evidence from this and other papers strongly
suggests an association between retinoblastoma and malignant melanoma.
Retinoblastoma is a rare childhood tumour which
can occur either unilaterally or bilaterally, and
which may be either familial or sporadic. Cases
known to be familial, and those with bilateral
disease, usually show a pattern of inheritance
consistent with the view that the occurrence of the
tumour is attributable to a dominant autosomal
gene with a penetrance of around 90%. We shall
refer to familial and bilateral cases as 'genetic'.
Patients who survive genetic retinoblastoma have
a substantial risk of developing osteosarcoma,
probably soft tissue sarcomas and possibly other
types of neoplasm. Reese et al. (1949) reported two
second tumours following treatment of 55 cases of
bilateral retinoblastoma with combined radiation
and surgery, and the high risk of second malignant
neoplasms in retinoblastoma survivors has
subsequently been well documented (Aherne, 1974;
Abramson et al., 1976; Meadows et al., 1980; 1985).
These second primary neoplasms can often be
attributed to radiotherapy but many cases have
been reported of second tumours occurring outside
the field of radiation treatment (Aherne, 1974;
Abramson et al., 1976), and, in some instances,
where no radiotherapy had been given (Abramson
et al., 1979). It has been suggested that patients
with genetic retinoblastoma are particularly
susceptible to the carcinogenic effects of radiation,
but there appears to be no direct quantitative
assessment of this apparent susceptibility. Indeed
little information is available on the actual
magnitude of the risk of second primary tumours
among retinoblastoma survivors.
Patients with the non-genetic form of the disease
do not appear to have a particularly high risk of
second neoplasms.
The association of other cancers with genetic
retinoblastoma can be manifested in ways other
than the increased risk to the survivors of
developing a second tumour. These may include an
increased risk of osteosarcoma in apparently
unaffected gene carriers (Gordon, 1974; Francois,
1977a), and a generally increased risk of cancer in
relatives of patients with retinoblastoma (Gordon,
1974; Bonaiti-Pellie & Briaid-Guillemot, 1980;
Fedrick & Baldwin, 1978; Strong et al., 1984).
The development of ectopic intracranial
retinoblastoma, thought possibly to arise in cells of
photoreceptor origin outside the retina, has been
reported by Bader et al. (1982) and has been
described as 'trilateral retinoblastoma'.
A chromosomal deletion associated with retino-
blastoma was originally reported by Lele et al.
(1963). It has since been shown that such cases
involve a deletion located on band q14 of
chromosome 13 and are sometimes associated with
congenital abnormality and mental defect.
Published cases were reviewed by Vogel (1979) and
many further reports have since appeared.
Knudson (1978) suggested that retinoblastoma
occurs as a result of two mutational events in
homologous genes on each of a pair of
chromosomes (i.e. that at the cell level it is a
recessive condition) and that in the genetic form of
the disease the first of these mutations is inherited.
He also suggested that the mutations leading to
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retinoblastoma involved chromosome 13, and might
create an 'immortal' cell line which continued to
divide rather than differentiating. Murphree and
Benedict (1984) suggested that the dominant allele
of the retinoblastoma gene is a 'suppressor' or
regulating gene, in the absence of which a
retinoblastoma can occur, and considered possible
mechanisms by which homozygosity or hemi-
zygosity of the recessive allele might arise at the cell
level.
In this paper we analyse the incidence rate of
second primary tumours among retinoblastoma
patients treated in Britain mainly between 1950 and
1977, particularly in relation to treatment and to
whether the patient had the genetic or non-genetic
form of the disease. We have also used these data
together with those from some additional patients
with double primary tumours to study the patterns
of occurrence of second tumours and to draw a
number of more qualitative conclusions.
Materials and methods
The analysis presented here is based on records of
children with retinoblastoma obtained from cancer
registries and hospitals in England, Scotland and
Wales. For the years 1962-1977 all cases notified to
the National Cancer Registration Scheme have been
included. For earlier years we have included only
three-year survivors from retinoblastoma ascertained
at certain hospitals and cancer registries. We shall
refer to the 882 patients in these two groups as the
'follow-up' series.
Information about the age of the child at
diagnosis of the retinoblastoma, whether the
tumour was unilateral or bilateral, whether there
was any known family history, methods of
treatment and other details were obtained through
cancer registries, hospitals and general practitioners.
Follow-up information was obtained both by
writing to general practitioners and hospitals and
through national record systems. In this way an
'effective follow-up' date was defined for each
patient; we are confident that all or virtually all of
the deaths or second primary tumours occurring
before this date will have been identified. The
effective follow-up date, or date of second primary
tumour or death, if earlier, has been used as a 'cut-
off' or 'censoring' date in the analyses described
below.
By these methods a total of 30 second primary
tumours were ascertained.
Nine further cases of retinoblastoma followed by
a second primary tumour, but not included in the
follow-up series, have been ascertained in other
ways: among children who were included in a
national survey of childhood cancer deaths there
were three who died of osteosarcoma having
previously been treated for retinoblastoma; a
further six patients were ascertained through the
records of their children who had themselves also
had retinoblastoma.
For each of the double primary tumours the
histological reports, or, wherever possible, the
original slides, have been reviewed.
We have classified children with bilateral
retinoblastoma and those for whom there is a
known family history as 'genetic' cases and the
remainder as 'non-genetic'. It is to be expected that
some of those classified as non-genetic will in fact
be unilateral cases with genetic retinoblastoma who
have been wrongly classified because we have no
record of a family history.
The treatment details recorded included the type
of radiotherapy used and, for external beam
radiotherapy, the tumour dose for each eye. For
patients given chemotherapy the names of all drugs
used were also recorded. Chemotherapy was
sometimes given as palliative treatment for patients
with metastases or whose retinoblastoma was at an
advanced stage. In this series there were no
survivors after extra-ocular recurrence of retino-
blastoma.
Results
Table I gives information about the 30 retino-
blastoma survivors in the follow-up series who were
discovered to have developed a second tumour.
This table and the subsequent analyses of second
primary tumours include all malignant neoplasms
and all neoplasms of the brain and CNS occurring
among the survivors, except for certain tumours of
the pineal and suprasellar regions - so-called
trilateral retinoblastoma. Table II shows the nine
other retinoblastoma survivors developing second
tumours but not included in the follow-up series.
A total of 268 patients were identified before
1962 of whom 131 (49%) had the genetic form of
retinoblastoma, and 614 were identified from 1962
to 1977 of whom 253 (41%) had the genetic form
of the disease. The rather high proportion of
genetic cases in the earlier period is accounted for
by the fact that some of these cases were identified
through centres specialising in the treatment of
retinoblastoma. The numbers of patients in each
category and the forms of treatment used, together
with the numbers of second tumours, are set out in
Table III.
Six further patients who survived their initial
treatment for retinoblastoma developed tumours in
the pineal and suprasellar regions, after intervals ofRETINOBLASTOMA AND SECOND PRIMARY NEOPLASMS 663
between two and six years. All of these children
had retinoblastoma in both eyes. The histology of
these 'trilateral' tumours is indistinguishable from
retinoblastoma; the tumours have therefore been
regarded as similar to bilateral retinoblastoma and
have not been included in our series of second
primary tumours. They are included in a paper on
ectopic intracranial retinoblastoma (Kingston et al.,
1985).
Second tumour type andpossible association with
treatment
Osteosarcoma It is well known that this is the
most common type of second tumour following
retinoblastoma. In the present series, osteosarcomas
developed in 21 retinoblastoma survivors: eight
were sited within the field of radiation and three
patients had additionally been given
cyclophosphamide. The other 13 patients all
developed osteosarcomas in the leg and five had
been given cyclophosphamide.
Soft tissue sarcomas Six patients developed second
tumours of this type, only two could be attributed
to radiotherapy given for retinoblastoma. One
patient was also treated with cyclophosphamide.
Brain tumours All three patients who developed
second neoplasms in the brain had been treated
with radiation, one had also been given
cyclophosphamide.
Leukaemia One patient had received radiotherapy
to both orbits and developed acute lymphatic
leukaemia within three years of his initial tumour.
Melanoma One patient developed a melanoma
within the radiation field seventeen years after
treatment for retinoblastoma; the second patient
whose melanoma developed after an interval of
nearly 30 years had not received radiotherapy.
Other epithelial tumours These tumours developed
after a much longer interval than most of the other
second neoplasms; none of them could be
attributed to radiation treatment. One patient
developed three separate neoplasms after
retinoblastoma; only the first of these tumours, an
adenocarcinoma of the cervix, has been included in
the analysis.
In the total of 39 patients included in Tables I
and II, 27 received radiation treatment for their
retinoblastoma. Fifteen of the second tumours
developed within the field of this radiation and it is
assumed that radiation is involved in their
causation. Cyclophosphamide was included in the
treatment of ten of the patients: the possible
importance of this as a carcinogenic factor is
discussed later.
Calculation ofincidence rates ofsecondprimary
tumours
In this and the following sections we give the
results of analyses of actuarially calculated
cumulative incidence rates of second tumours for
the 882 patients in the follow-up series. The method
used, which allows for varying lengths of follow-up
for the patients included in the series, is that of
Peto et al. (1976, 1977), normally used for the
analysis of survival data: in the present context
'survival' is interpreted as survival free of a second
tumour.
For all cases taken together the incidence of
second primary tumours is estimated to be 2.0% at
12 years after diagnosis and 4.2% after 18 years.
However such overall rates do not mean very
much, and cannot, for instance, be used to compare
different series because they depend on the
proportions of genetic and non-genetic cases and on
the number of patients given radiotherapy. These,
and possibly other factors, will affect the chance
that a second tumour will develop.
Secondprimary tumours occurring among the genetic
cases in thefollow-up series
Most of the second tumours in the follow-up series,
26 out of 30 cases, occurred among the 384 genetic
cases, 25 in patients with bilateral tumours and the
remaining one in a patient with a known family
history of retinoblastoma. Actuarially calculated
cumulative incidence rates at 12 and 18 years after
the initial diagnosis are presented in Table IV.
(Cases 6 and 7 in Table I are included in Table IV
but for these patients the second tumours occurred
after the date which defined the period of follow-up
and they are therefore excluded from all analyses of
incidence rates.) At 18 years after diagnosis the
estimated rate of second primary tumours is 8.4%;
for osteosarcomas alone the corresponding rate is
6.0%.
Tumours outside the radiation field As shown in
Table IV, 12 of the 26 second primaries among the
cases of genetic retinoblastoma developed outside
the radiation field. Of these tumours, nine were
osteosarcomas, two were soft-tissue sarcomas and
one an epithelial tumour. The estimated cumulative
incidence rate 18 years after the diagnosis of
retinoblastoma is 3.0%, all of the second tumours
observed within this period being osteosarcomas.
An estimate of the inherent risk of osteosarcoma
among patients with genetic retinoblastoma can be664 G.J. DRAPER et al.
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Table Ill Second primary neoplasms occurring among patients in 'follow-up series' according to type of retinoblastoma,
year ofdiagnosis and type oftreatment (second tumours/patients)
Radiotherapy No radiotherapy
Type of Year of
retinoblastoma diagnosis Chemotherapy No chemotherapy All Chemotherapy No chemotherapy All
Genetic Pre 1962 1/11 10/101 11/112 0/0 2/19 2/19
1962-77 8/62 4/140 12/202 1/3 0/48 1/51
All years 9/73 14/241 23/314 1/3 2/67 3/70
Non-genetic Pre-1962 0/1 2/24 2/25 0/0 2/112 2/112
1962-77 0/21 0/54 0/75 0/8 0/278 0/286
All years 0/22 2/78 2/100 0/8 2/390 2/398
Total All years 9/95 16/319 25/414 1/11 4/457 5/468
Table IV Actuarially calculated cumulative incidence rates of second primary neoplasms among patients with genetic
retinoblastoma
All second neoplasms Osteosarcoma
Cumulative rate % Cumulative rate %
Site ofsecond Treatment Patients
neoplasm group at risk No. At 12y At 18y No. At 12y At 18y
All sites All 384 26 4.3 8.4 17 3.6 6.0
Inside field of radiation Radiotherapy 314 14 3.4 6.6 8 2.4 3.7
Outside field of radiation All 384 12 1.6 3.0 9 1.6 3.0
(includes non-irradiated) No chemotherapy 308 7 1.0 2.2 4 1.0 2.2
obtained by considering only the osteosarcomas
occurring outside the radiation field, and excluding
all patients who received chemotherapy. There were
308 such patients and in four of them an
osteosarcoma developed in a leg-bone. This gives
an actuarially estimated rate of 2.2% by 18 years.
For the population in general about one person in
10,000 would develop an osteosarcoma during a
similar period. (The majority of such tumours occur
in the long bones of the leg.) The risk for patients
with the genetic form of retinoblastoma, excluding
any risk from treatment, is therefore estimated to be
about 200 times that for the general population.
Since this ratio is based on only four cases, the
estimate is very imprecise; 95% confidence limits
are approximately 50 and 500.
Tumours within the radiation field Table IV also
shows the incidence rate for tumours within the
radiation field for genetic cases receiving
radiotherapy. We have, as explained above,
included in this category the two brain tumours, the
melanoma of the forehead, and the leukaemia, as
well as the osteosarcomas and fibrosarcomas of the
orbit, maxilla and nasal bones. These 14 tumours
give an estimated incidence rate by 18 years of
6.6%. The corresponding rate for osteosarcomas
alone is 3.7%. Osteosarcomas of the orbit are very
rare, and probably less than 10% of all
osteosarcomas occur at any site in the skull and jaw
bones in this age-group; we would expect that less
than one person in 100,000 would develop such a
tumour in the first 20 years of life. The observed
rate is of the order of 4000 times as great as this.
Comparisons ofincidence rates between various
sub-groups ofcases
In the next two sections we compare the incidence
rates of second primary neoplasms between patients
with genetic and non-genetic retinoblastoma and
then between patients given or not given
chemotherapy. In most cases we have not been able
to give statistical significance levels, first because
some of the rates are calculated in a non-standard
way and secondly because the small numbers of
second tumours observed mean that the usual
approximations are not valid here. Also the number
of overlapping analyses carried out and the
differences in radiotherapy regimes for the sub-
groups of cases of interest vitiate such analyses. The
conclusions suggested here must therefore beRETINOBLASTOMA AND SECOND PRIMARY NEOPLASMS 667
regarded as tentative and awaiting confirmation.
We believe, nevertheless, that they are reasonable in
the light of other knowledge about retinoblastoma.
Comparisons between the incidence ofsecond
primary tumours in patients with the genetic and
non-geneticforms ofretinoblastoma
Among the 498 patients classified, on the evidence
available to us, as having the non-genetic form of
retinoblastoma only four second primary tumours
were recorded, three outside and one inside the
field of radiation. Only one of these four tumours,
an osteosarcoma of the fibula, occurred in the first
18 years following the diagnosis of retinoblastoma;
it seems probable that this patient did in fact have
the genetic form of the disease. The incidence rate
for second primary tumours outside the field of
radiation, based on this one case is 0.4% at 18
years; if this case was indeed wrongly classified the
rate is zero. The corresponding rate for the genetic
cases is 3.0%.
For tumours inside the field of radiation the
contrast between the rates for genetic and non-
genetic cases is also striking: the only such tumour
in the 100 patients with non-genetic retinoblastoma
given radiotherapy, a meningioma of the brain,
occurred 31 years after treatment; the estimated
rates for the patients with genetic retinoblastoma
are 3.4% at 12 years and 6.6% at 18 years.
Ideally the analysis of radiation-induced second
tumours should take account of the dose and type
of radiotherapy, and in a subsequent study we
propose to carry out such an analysis. In the
treatment of patients reported here several different
forms of implant as well as external beam
radiotherapy were used; for the latter the doses
ranged from 12 to 75Gy, though the majority were
in the range 35-40Gy. For the present paper we
have simply re-analysed the data on the occurrence
of second primaries in the field of radiation taking
into account the number of eyes irradiated rather
than the number of patients, and calculating
tumour rates per 100 eyes irradiated. For patients
with genetic retinoblastoma a total of 380 eyes were
irradiated and 14 tumours were observed within the
field of radiation; the cumulative rates of
occurrence of such tumours are 2.9% after 12 years
and 5.7% after 18 years. These rates are less than
those quoted for the incidence rates in terms of
numbers of patients because the number of eyes
irradiated is greater than the number of patients.
For the 100 patients with non-genetic retino-
blastoma (always unilateral) no second primaries
were observed within the field of radiation in the 18
years after diagnosis. These results suggest that
patients with the genetic form ofretinoblastoma may
be more susceptible to the induction of second
tumours by radiation, though we have not taken into
accountdifferences in radiation doses betweengenetic
and non-genetic cases.
The effects of chemotherapy are discussed in the
next section. Chemotherapy was used for a greater
proportion of genetic than of non-genetic cases but
this does not appear to account for the higher
incidence of second primaries in the genetic cases.
Effect ofchemotherapy
Ninety patients received cyclophosphamide as part
of their initial treatment for retinoblastoma,
sometimes in combination with other drugs. Ten of
these patients developed second primary tumours,
eight osteosarcomas, one fibrosarcoma and one
glioblastoma. Sixteen patients received other forms
of chemotherapy and none of these developed a
second tumour.
The majority of the patients who received
chemotherapy were genetic cases who also received
radiotherapy; chemotherapy was seldom used
before 1962 and our records for earlier years are
incomplete. We have therefore restricted the
detailed analysis of the possible risks associated
with chemotherapy to patients with the genetic
form of retinoblastoma treated from 1962 onwards.
Table V shows the second neoplasm rates for
patients with genetic retinoblastoma treated in the
years 1962-1977: the patients treated with
chemotherapy are compared with those who
received none with respect to (a) all neoplasms
occurring among patients given radiotherapy, (b)
all neoplasms among those not given radiotherapy,
(c) neoplasms in the radiation field, and (d)
neoplasms outside the radiation field. For each of
these comparisons the incidence of second primary
tumours is greater among patients given
chemotherapy than among those not given it,
though of course the second neoplasms in (a) and
(b) are the same as those in (c) and (d). The
estimated incidence rates 12 years after diagnosis
for tumours inside the field of radiation are 4.2%
for patients given chemotherapy in addition to
radiation and 2.9% for patients not given
chemotherapy. The rates for tumours outside the
field of radiation (and including also patients who
were not irradiated at all) are 4.6% and 1.0%
respectively for patients with and without
chemotherapy. At 18 years after diagnosis the
contrasts are even more striking. For tumours
inside the field an analysis taking into account the
numbers of eyes irradiated yields similar results.
For reasons given above, and in particular the fact
that patients who received chemotherapy were also
more likely to have had repeated courses of
radiotherapy which might have been responsible for
the higher incidence of second primaries in this668 G.J. DRAPER et al.
Table V Actuarially calculated cumulative incidence rates of second primary neoplasms among patients with genetic
retinoblastoma treated between 1962 and 1977
Treated with chemotherapy No chemotherapy
Second neoplasms Second neoplasms
Cwnulative rate % Cumulative rate %
Site ofsecond Patients Patients
neoplasm Radiotherapy at risk No. At 12y At 18y at risk No. At 12y At 18y
All sites Yes 62 8 6.5 14.7 140 4 4.2 4.2
No 3 1 (100) (100) 48 0 0 0
Inside field ofradiation Yes 62 4 4.2 9.9 140 3 2.9 2.9
Outside field of radiation Yes and No 65 5 4.6 7.5 188 1 1.0 1.0
group, it is difficult to assess the statistical
significance of the findings. The overall difference
in the incidence of second primaries for patients
with and without chemotherapy is, however,
formally significant (P<0.05, one-tailed test) after
allowing simply for whether any form of
radiotherapy was used, and it appears that there
is a strong prima facie case for believing that
chemotherapy is implicated in the induction of
second primary tumours in these patients. The
finding of an increased incidence of second primary
tumours outside the field of radiation in patients
treated with chemotherapy is strengthened by the
observation of two further chemotherapy-associated
cases (numbers 6 and 7 in Table I) occurring after
the date of last follow-up used for the analysis of
incidence rates (these cases are included in the
counts of cases in the tables, but excluded from the
calculation ofincidence rates).
The results reported here relate only to
cyclophosphamide, and it is not possible to say
whether they apply to chemotherapy generally.
Discussion
The susceptibility ofpatients with genetic
retinoblastoma to the induction ofsecond tumours
It has been suggested that patients with the genetic
form of retinoblastoma may have an increased
susceptibility to the induction of second tumours by
radiation. This hypothesis is extremely difficult to
test since other individuals exposed to radiation
differ from retinoblastoma patients in respect of the
doses received, the area irradiated and the type of
tissue exposed. Strong (1977) suggested that
differences between induction times for radiogenic
sarcomas in retinoblastoma patients and others
exposed to radiation provided some evidence of
increased susceptibility, and, specifically, that this
predisposition might be due to the fact that the
retinoblastoma patients had already inherited the
first mutational event. Weischelbaum et al. (1977)
reported an increased sensitivity (in terms of cell
survival) to X-radiation of fibroblasts from a
patient with a 13q-deletion. Subsequent papers have
given apparently conflicting results; the laboratory
evidence has been reviewed by Morten (1986).
The most direct test of the hypothesis is to
compare patients with the genetic and non-genetic
forms of reinoblastoma treated by irradiation. In
the present series the rate of second tumours among
the eyes of patients with genetic retinoblastoma is
greater than the rate among the eyes for the non-
genetic patients. It is obviously important that
other large series should be analysed in the same
way.
Secondprimary tumours observed in other series
Osteosarcoma Numerous osteosarcomas have
been reported following genetic retinoblastoma.
This is certainly the most common type of second
primary and occurs in the 20 years following the
diagnosis of retinoblastoma at a rate hundreds of
times greater than that in the general population.
These tumours occur both as a result of, and
independently of, radiation.
Soft tissue sarcomas It seems likely that retino-
blastoma patients are also at an increased risk of
developing other forms of sarcoma, but these are
much less common than osteosarcoma. In addition
to the six patients mentioned in this paper,
previously reported cases have included fibro-
sarcoma and rhabdomyosarcoma.
Brain tumours If we exclude ectopic intracranial
retinoblastomas which have been discussed aboveRETINOBLASTOMA AND SECOND PRIMARY NEOPLASMS 669
we have been able to find a published report of
only two other brain tumours following
retinoblastoma (Jensen & Miller, 1971). One was a
spongioblastoma where no radiotherapy had been
administered; for the other patient the method of
treatment and histological type of brain tumour are
not recorded. Other cases of brain tumours
following retinoblastoma may well be included
among some of the large series which have been
reported.
Leukaemia There have been at least five other
published reports of leukaemia following retino-
blastoma (Magnasco et al., 1967; Hoefnagel et al.,
1973; Francois, 1977b; Tefft et al., 1968; White
et al., 1985). Two of these had received no
radiation treatment for their first tumours, the
other three had been given radiotherapy, two in
conjunction with chemotherapy.
Melanoma In addition to the two patients
presented here there have been reports of at least
ten cases of melanoma following retinoblastoma
(Meadows et al., 1985; Abramson et al., 1984; Tefft
et al., 1968). For these published cases the
melanomas developed either in patients who had
not been irradiated or outside the field of radiation.
It is possible that some of the reports quoted here
refer to the same cases but, with this caveat, there
appears to be strong evidence for an association
between retinoblastoma and malignant melanoma.
Other epithelial tumours Six other cases of
epithelial tumours occurred in the present series.
They, like the great majority of cases in the
population in general, occurred in adult life and it
is difficult to say whether retinoblastoma survivors
have an increased incidence of such tumours.
Nuutinen et al., (1982) have reviewed reports of 15
epithelial tumours (including 3 melanomas)
occurring in retinoblastoma survivors. The interval
between the diagnoses of retinoblastoma and the
subsequent epithelial tumours varied between 9 and
37 years.
Previous estimates ofthe incidence ofsecondprimary
tumours in retinoblastoma survivors
Although the increased risk of second primary
tumours among survivors of the genetic form of
retinoblastoma is well recognised, none of the
previously published reports permits direct
comparison with the results given here. There are
many reports of individual cases or small groups of
cases but there are only two or three previously
published large series for which estimates of risk
can be made. These estimates must be interpreted
with some caution since they may be expected to
depend on the doses of radiotherapy and possibly
chemotherapy used in treatment, the length of
follow-up, and whether all second tumours are
considered or, for instance, only those developing
outside the field of radiation.
The largest reported series of patients is that
from Columbia Presbyterian Medical Center, New
York, which has been analysed in a number of
papers by Abramson et al. (1976, 1984), Jensen and
Miller (1971), Sagarman et al. (1969) and Kitchin
and Ellsworth (1974). In one of these papers the
series was analysed jointly with that from the
American Forces Institute of Pathology (Abramson
et al., 1976) giving a total of 2300 cases, though it
appears that there is some duplication of patients
between the two series and that the true total is less
than this. The spectrum of histological types of
second primary tumours in these papers is similar
to that described in the present paper. Other points
of similarity are the findings that nearly all the
second primary tumours occur among the bilateral
cases and that many of these tumours occur outside
the radiation field and some among non-irradiated
cases. Abramson et al. (1976) suggested that in
retinoblastoma patients the incidence of osteo-
sarcoma of the femur, the most common site of
occurrence of second tumours outside the field of
radiation, is 500 times that for the general
population; this is consistent with our results. In
further papers on this series of patients, Abramson
and his colleagues have presented data on the
incidence of second primary tumours in non-
irradiated patients, in patients given bilateral
irradiation, and in patients given at least two
courses of external beam radiotherapy.
Most recently, using actuarial methods of
analysis, they have calculated the incidence of
second tumours in patient with genetic retino-
blastoma to be 20% after ten years survival and
90% after 30 years survival (Abramson et al.,
1984). The difference between these results and our
own suggests either that we have failed to ascertain
all cases of second tumours (though we do not
think it likely that any appreciable number have
been missed) or that Abramson and his colleagues
have been more successful in following-up patients
who do develop second tumours than those who
remain unaffected: this would decrease the numbers
apparently at risk and increase the calculated rate.
Francois et al. (1980) reported a series of 85
retinoblastoma patients followed up for periods
between 4 and 30 years. Eight second tumours were
observed among 39 bilateral cases, three in the field
of radiation.
Tucker et al. (1984) present data on 20 second
tumours among 319 retinoblastoma patients who
had survived at least two years from diagnosis.
Grouping together unilateral and bilateral cases and670 G.J. DRAPER et al.
including second tumours of all types and sites,
they found that the incidence of second tumours
during an average further follow-up of seven years
was 60 times as large as would be expected from
population rates for malignant neoplasms, the rate
for bone tumours being 1000 times the population
rate.
Cyclophosphamide and the induction ofsecond
primary tumours
It is well known that treatment by alkylating agents
may cause subsequent cancers. In particular, cyclo-
phosophamide causes bladder cancer, probably
acute non-lymphocytic leukaemia and possibly
squamous cell carcinoma of the skin (International
Agency for Research on Cancer, 1981; Schmahl et
al., 1982). There are also case reports of a variety
of other tumours following the use of this drug. In
many of these reports the evidence is difficult to
evaluate since cyclophosphamide is often used in
combination with other cytotoxic drugs.
The analyses in the present paper, though based
on rather small numbers, suggest the possibility
that cyclophosphamide may be responsible for the
induction of second tumours in retinoblastoma
patients. Patients given cyclophosphamide were,
however, also more likely to have received radio-
active implants or multiple courses of radiotherapy,
so it is possible that the risk apparently associated
with cyclophosphamide may in fact be attributable
to the radiotherapy given at the same time. White
et al. (1985) have published a report of a child
treated for unilateral retinoblastoma with radiation
and drugs which included cyclophosphamide and
who developed acute non-lymphocytic leukaemia
five years later. There appear to be no other
published reports directly relating to the possible
role of any form of chemotherapy in the induction
of second tumours among retinoblastoma patients.
Among a group of 42 children treated
conservatively for retinoblastoma, Francois (1977b)
reported four who developed second malignant
neoplasms: three osteosarcomas and one leukaemia.
These four children had all received cyclo-
phosphamide as part of their initial treatment
(personal communication).
Osteosarcomas have been reported following
chemotherapy, which included cyclophosphamide,
used for the treatment of Ewing's tumour (Strong
et al., 1979).
It is possible that patients carrying the retino-
blastoma gene are particularly susceptible to the
carcinogenic effects both of radiation and cyclo-
phosphamide. From our data it is not possible to
say whether the increased risk, if any, extends to
other drugs since no other drug has been
extensively used in Britain in the treatment of
retinoblastoma.
There appears to be no published evidence that
chemotherapy is of benefit other than palliative in
the treatment of retinoblastoma. In view of the
findings presented in this paper it is essential that
other sets of data should be analysed to determine
whether or not there is an increased risk of second
tumours associated with the use of chemotherapy
so that the possible hazards, if any, can be taken
into account in planning treatment protocols.
We thank the many consultants and general practitioners
who provided the information on which this paper is
based, and in particular Dr H.B. Marsden of the
Department of Pathology, University of Manchester, who
reviewed the histology. We are grateful to the Office of
Population Censuses and Surveys, the Information
Services Division of the Common Services Agency of the
Scottish Health Service, the Registrar General for
Scotland, and regional cancer registries for providing
copies of notifications of childhood cancer cases. We
thank the National Health Service Central Registers at
Southport and Edinburgh for notification of deaths and
the 'flagging' of survivors. We are grateful to Dr L.M.
Kinnier Wilson for providing data from the Oxford
Survey of Childhood Cancers, to Mr D. Corney, Mrs L.
Curtice, Mr C.W.P. Fearnley, Mr M.M. Hawkins and Dr
M. Potok for help with computing and with the records
of retinoblastoma patients, and to Mrs E.M. Roberts for
her part in collecting the medical records and for
secretarial help.
The Childhood Cancer Research Group is supported by
the Department of Health and Social Security and the
Scottish Home and Health Department. The Long Term
Follow-up Study of childhood cancer survivors is
supported by the Cancer Research Campaign and the
Leukaemia Research Fund.
References
ABRAMSON, D.H., ELLSWORTH, R.M. & ZIMMERMAN,
L.E. (1976). Non-ocular cancer in retinoblastoma
survivors. Trans. Am. Acad. Ophth. Otolaryngol., 81,
454.
ABRAMSON, D.H., BONNER, H.J. & ELLSWORTH, R.M.
(1979). Second tumours in non-irradiated bilateral
retinoblastoma. Am. J. Ophth., 86, 624.
ABRAMSON, D.H., ELLSWORTH, R.M., KITCHIN, D. &
TUNG, G. (1984). Second non-ocular tumours in
retinoblastoma survivors. Ophthalmology, 91, 1351.
AHERNE, G. (1974). Retinoblastoma associated with
other primary malignant neoplasms. Trans. Ophth.
Soc. U.K., 94, 938.RETINOBLASTOMA AND SECOND PRIMARY NEOPLASMS 671
BADER, J.L., MEADOWS, A.T., ZIMMERMAN, L.E. & 4
others (1982). Bilateral retinoblastoma with ectopic
intracranial retinoblastoma: trilateral retinoblastoma.
Cancer Genet. Cytogenet., 5, 203.
BONAITI-PELLIE, C. & BRIAID-GUILLEMOT, M.L. (1980).
Excess of cancer deaths in grand-parents of patients
with retinoblastoma. J. Med. Genet., 17, 95.
FEDRICK, J. & BALDWIN, J.A. (1978). Incidence of cancer
in relatives of children with retinoblastoma. Br. Med.
J., 1, 83.
FRANCOIS, J. (1977a). Retinoblastoma and osteogenic
sarcoma. Ophthalmologica, 175, 185.
FRANCOIS, J. (1977b). Conservative treatment of retino-
blastoma. Mod. Probl. Ophth., 18, 113.
FRANCOIS, J., DE SUTTER, E., COPPIETERS, R. & DE BIE,
S. (1980). Late extraocular tumours in retinoblastoma
survivors. Ophthalomologica, 181, 93.
GORDON, H. (1974). Family studies in retinoblastoma. In
Medical Genetics Today, Bergsma & 3 others (eds) p.
185. Johns Hopkins University Press, Birth Defects:
Original Article Series 10.
HOEFNAGEL, D., McINTYRE, O.R., STORRS, R.C.,
SULLIVAN, P.B. & MAURER, L.H. (1973). Retino-
blastoma followed by acute lymphoblastic leukaemia.
Lancet, i, 725.
INTERNATIONAL AGENCY FOR RESEARCH ON
CANCER, LYON, (1981). Some anti-neoplastic and
immunosuppressive agents. IARC Monographs on the
evaluation of the carcinogenic risk of chemicals to
humans. 26, 165.
JENSEN, R.D. & MILLER, R.W. (1971). Retinoblastoma:
Epidemiologic characteristics. N. Engl. J. Med., 285,
307.
KINGSTON, J.E., PLOWMAN, P.N. & HUNGERFORD, J.L.
(1985). Ectopic intracranial retinoblastoma in
childhood. Br. J. Ophth., 69, 742.
KITCHIN, F.D. & ELLSWORTH, R.M. (1974). Pleiotropic
effect of the gene for retinoblastoma. J. Med. Genet.,
11, 244.
KNUDSON, A.G. (1978). Retinoblastoma: A prototypic
hereditary neoplasm. Seminars Oncol., 5, 57.
LELE, K.P., PENROSE, L.S. & STALLARD, H.B. (1963).
Chromosome deletion in a case of retinoblastoma.
Ann. Hum. Genet., 27, 171.
MAGNASCO, A., ZINGIRIAN, M. & COTTAFAVA, F.
(1967). Su un raro caso di leucemia istoide a rapida
evoluzione, insorta dopo trattamento roentgenterapico
ed antiblastico per retinoblastoma. Ann. Ottal., 93,
300.
MEADOWS, A.T., STRONG, L.C., LI, F.P. & 6 others (1980).
Bone sarcoma as a second malignant neoplasm in
children. Cancer, 46, 2603.
MEADOWS, A.T., BAUM, E., FOSSATI-BELLAMI, F. & 10
others (1985). Second malignant neoplasms in children:
An update from the Late Effects Study Group. J. Clin.
Oncol., 3, 532.
MORTEN, J.E.N. (1986). Cellular studies on retinoblastoma.
Int. J. Radiation Biol., 49 (in press).
MURPHREE, A.L. & BENEDICT, W.F. (1984). Retino-
blastoma: clues to human oncogenesis. Science, 223,
1028.
NUUTINEN, J., KARJA, J. & SAINIO, P. (1982). Epithelial
second malignant tumours in retinoblastoma survivors.
Acta Ophth., 60, 133.
PETO, R., PIKE, M.C., ARMITAGE, P. & 7 others (1976,
1977). Design and analysis of randomised clinical trials
requiring prolonged observation of each patient. I:
Introduction and design. II: Analysis and examples.
Br. J. Cancer, 34, 585, 35, 1.
REESE, A.B., MERRIAM, G.R. & MARTIN, H.E. (1949).
Treatment of bilateral retinoblastoma by irradiation
and surgery. Am. J. Ophth., 32, 175.
SAGARMAN, R.H., CASSADY, J.R., TRETTER, R.P. &
ELLSWORTH, R.M. (1969). Radiation-induced
neoplasia following external beam therapy for children
with retinoblastoma. Am. J. Roent., 105, 529.
SCHMAHL, D., HABS, M., LORENZ, M., M & WAGNER, I.
(1982). Occurrence of second tumours in man after
anticancer drug treatment. Cancer Treatment Rev., 9,
167.
STRONG, L.C. (1977). Theories of pathogenesis: Mutation
and cancer. In Genetics ofHuman Cancer, Mulvihill &
2 others, (eds) p. 401. Raven Press: New York.
STRONG, L.C., HERSON, J., OSBORNE, B.M. & SUTOW,
W.W. (1979). Risk of radiation related subsequent
malignant tumours in survivors of Ewing's sarcoma. J.
Natl Cancer Inst., 62, 1401.
STRONG, L.C., HERSON, J., HAAS, C. & 4 others (1984).
Cancer mortality in relatives of retinoblastoma
patients. J. Natl Cancer Inst., 73, 303.
TEFFT, M., VAWTER, G.F. & MITUS, A. (1968). Second
primary neoplasms in children. Am. J. Roent., 103,
800.
TUCKER, M.A., MEADOWS, A.T., BOICE, J.D., HOOVER,
R.N. & FRAUMENI, J.F. (1984). Cancer risk following
treatment of childhood cancer. In Radiation
Carcinogenesis: Epidemiology and Biological
Significance. Boice & Fraumeni Jr. (eds) p. 211. Raven
Press: New York.
VOGEL, F. (1979). Genetics of retinoblastoma. Hum.
Genet., 52, 1.
WEICHSELBAUM, R.R., NOVE, J. & LITTLE, J.B. (1977).
Skin fibroblasts from a D-deletion type retinoblastoma
patient are abnormally X-ray sensitive. Nature, 266,
726.
WHITE, L., ORTEGA, J.A. & YING, K.L. (1985). Acute non-
lymphocytic leukaemia following multi-modality
therapy for retinoblastoma. Cancer, 55, 496.